Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orismilast and Midazolam DDI Study
NCT02753218Phase 1Terminated
- Sponsor
- LEO Pharma
- Start
- Apr 2016
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of orismilast in Psoriasis vulgaris (PV), sponsored by LEO Pharma. Primary endpoints: Area under the plasma concentration versus time curve at Day 17 and Peak Plasma Concentration at Day 17. Started Apr 2016; status: terminated.
02
Drugs
orismilast
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT02753218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02753218.